|
"siveke jt"的相关文件
显示项目 1-10 / 28 (共3页)
1 2 3 > >>
每页显示[10|25|50]项目
| 國家衛生研究院 |
2020-10-10 |
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1
|
Chen, LT;Macarulla, T;Blanc, JF;Mirakhur, B;de Jong, FA;Belanger, B;Bekaii-Saab, T;Siveke, JT |
| 國家衛生研究院 |
2020-01 |
Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: Subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial
|
Macarulla Mercade, T;Chen, LT;Li, CP;Siveke, JT;Cunningham, D;Bodoky, G;Blanc, JF;Lee, KH;Dean, A;Belanger, B;Wang-Gillam, A |
| 國家衛生研究院 |
2019-07-28 |
Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer
|
Chen, LT;Macarulla, T;Blanc, JF;Mirakhur, B;Jong, FA;Belanger, B;Bekaii-Saab, T;Siveke, JT |
| 國家衛生研究院 |
2019-03-04 |
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial
|
Macarulla, T;Blanc, JF;Wang-Gillam, A;Chen, LT;Siveke, JT;Mirakhur, B;Chen, J;de Jong, FA |
| 國家衛生研究院 |
2019-02 |
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
|
Wang-Gillam, A;Hubner, RA;Siveke, JT;Von Hoff, DD;Belanger, B;de Jong, FA;Mirakhur, B;Chen, LT |
| 國家衛生研究院 |
2019-01 |
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Hubner, RA;Cubillo, A;Blanc, JF;Melisi, D;Von Hoff, DD;Wang-Gillam, A;Chen, LT;Becker, C;Mamlouk, K;Belanger, B;Yang, Y;de Jong, FA;Siveke, JT |
| 國家衛生研究院 |
2018-11-07 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
|
Chen, LT;Siveke, JT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, FS;Mamlouk, K;Belanger, B;de Jong, FA;Hubner, RA |
| 國家衛生研究院 |
2018-02 |
Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan
|
Siveke, JT;Hubner, R;Macarulla, TM;Wang-Gillam, A;Dean, AP;Blanc, JF;Cunningham, D;Mirakhur, B;Belanger, B;de Jong, FA;Chen, LT |
| 國家衛生研究院 |
2018-02 |
Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g
|
Macarulla, TM;Hubner, R;Blanc, JF;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Yanshen, S;Jameson, GS;Lee, KH;Chiu, CF;Schwartsmann, G;Braiteh, FS;Cunningham, D;Chen, LT;Von Hoff, DD;Mamlouk, KK;de Jong, FA;Siveke, JT |
| 國家衛生研究院 |
2018-02 |
Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) p
|
Macarulla, TM;Siveke, JT;Dean, AP;Hubner, R;Blanc, JF;Cunningham, D;Chen, LT;Mirakhur, B;Chen, J;de Jong, FA;Wang-Gillam, A |
显示项目 1-10 / 28 (共3页)
1 2 3 > >>
每页显示[10|25|50]项目
|
